Recent findings demonstrate that loss of ERAAP, an endoplasmic reticulum aminopeptidase involved in antigen processing, plays a key role in stimulating anti-tumor innate and adaptive immune responses. We show that MHC class I molecules produced in the absence of ERAAP retain their capability of presenting antigens to CD8(+) T cells, but not of inhibiting NK cells.
Fruci, D., Locatelli, F., Cifaldi, L., ERAAP modulation: A possible novel strategy for cancer immunotherapy?, <<ONCOIMMUNOLOGY>>, 2012; 1 (1): 81-82. [doi:10.4161/onci.1.1.17828] [https://hdl.handle.net/10807/244439]
ERAAP modulation: A possible novel strategy for cancer immunotherapy?
Locatelli, Franco;
2012
Abstract
Recent findings demonstrate that loss of ERAAP, an endoplasmic reticulum aminopeptidase involved in antigen processing, plays a key role in stimulating anti-tumor innate and adaptive immune responses. We show that MHC class I molecules produced in the absence of ERAAP retain their capability of presenting antigens to CD8(+) T cells, but not of inhibiting NK cells.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ERAAP modulation A possible novel strategy for cancer immunotherapy.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Note: Creative Commons Attribution-NonCommercial 3.0
Licenza:
Creative commons
Dimensione
835.7 kB
Formato
Adobe PDF
|
835.7 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
